Clinical trial
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or…
NCT00005786 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00005786 |
|---|---|
| Title | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia |
| Official title | A Pilot Study of Arsenic Trioxide in the Treatment of Relapsed and Refractory Indolent Lymphomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Study type | Interventional |
| Conditions | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Prolymphocytic Leukemia, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma and 1 more |
| Intervention type | Drug, Other |
| Interventions | arsenic trioxide, laboratory biomarker analysis |
| Enrollment | 25 |
| Start date | Jan 1, 2001 |
| Primary completion | Nov 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 1, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: